SGLT2 inhibitors also reduced the risk of CV death and HF hospitalization in a large clinical trial targeting patients with HF with mildly reduced ejection fraction (HFmrEF) or with preserved ejection fraction (HFpEF).8,9 Accordingly, adding empagliflozin or dapagliflozin to drug therapy is recommended for patients with HF across all ranges of left ventricular ejection fraction (LVEF).10 Through these randomized clinical trials, SGLT2 inhibitors have been confirmed to induce CV effects and to have hypoglycemic mechanisms. Here, SLC5A2 is linked to hydrops fetalis.